BPK-29 is a potent and selective NR0B1 ligand th at covalently binds to NR0B1 Cys 274. BPK-29 inhibits the NR0B1-SNW1 interaction. It inhibits the anchorage-independent growth of KEAP1-mutant cancer cells.', 'BPK-29 is a small molecule inhibitor th at blocks the nuclear factor erythroid 2–related factor 2 (NRF2) pathway. It targets the cysteine 274 residue in the nuclear receptor subfamily 0 group B member 1 (NR0B1) and disrupts protein-protein interactions in non-small-cell lung cancer (NSCLC) cell proteomes.
